50
13
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T80558 |
Anti-Mouse CD117 Antibody
|
c-Kit | Tyrosine Kinase/Adaptors |
Anti-Mouse CD117 Antibody 为专针对小鼠CD117的IgG2b类免疫抑制抗体,其宿主源自大鼠。 | |||
T3452 |
ISCK03
|
c-Kit | Tyrosine Kinase/Adaptors |
ISCK03 是一种特异性的 SCF/c-Kit 抑制剂。 | |||
T5409 |
AZD3229
|
c-Kit | Tyrosine Kinase/Adaptors |
AZD3229 是一种突变型酪氨酸激酶受体抑制剂,可用于胃肠道间质瘤的研究。 | |||
T9689 |
M4205
|
c-Kit | Tyrosine Kinase/Adaptors |
M4205 是一种 c-Kit 抑制剂,对外显子 11、13、17 中的 c-Kit 突变具有高活性。 | |||
T4320 |
Flumatinib
HHGV678 |
Bcr-Abl; PDGFR; c-Kit | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Flumatinib (HHGV678) 是一种具有口服活性的选择性 Bcr-Abl 抑制剂,能够作用于 c-Abl (IC50:1.2 nM),PDGFRβ (IC50:307.6 nM) 和 c-Kit (IC50:665.5 nM)。 | |||
T5109 |
Avapritinib
BLU-285 |
PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Avapritinib (BLU-285) 是选择性的、高效的、具有口服活性的 KIT 和 PDGFRA 激活环突变激酶抑制剂,能够作用于 KIT D816V (IC50:0.27 nM) 和 PDGFRA D842V (IC50:0.24 nM)。它减弱 ABCB1 和 ABCG2 的传输功能。它与激酶的活性构象结合,并显示抗肿瘤活性。 | |||
T7945 |
SU14813
|
VEGFR; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
SU14813 是一种多靶点受体酪氨酸激酶抑制剂,能够抑制 VEGFR2 (IC50:50 nM),VEGFR1 (IC50:2 nM),PDGFRβ (IC50:4 nM),KIT (IC50:15 nM)。 | |||
T2288 |
Motesanib
AMG 706,莫特塞尼,莫替沙尼 |
VEGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Motesanib (AMG 706) 是有效的、ATP 竞争性的 VEGFR1/2/3 的抑制剂,其IC50值为 2 nM/3 nM/6 nM,与对 Kit 的选择性相似,是 PDGFR 和 Ret 的 10 倍多。 | |||
T6166 |
Telatinib
Bay 57-9352,替拉替尼 |
VEGFR; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Telatinib (Bay 57-9352) 是一种口服具有活力的,小分子的 VEGFR2,VEGFR3,PDGFα 和 c-Kit 抑制剂,它们的 IC50 值分别为6,4,15,1 nM。 | |||
T4332 |
c-Kit-IN-1
PDGFR inhibitor 1,DCC-2618 |
c-Met/HGFR; c-Kit | Tyrosine Kinase/Adaptors |
c-Kit-IN-1 (DCC-2618) 是c-Kit 和c-Met 抑制剂(IC50<200 nM)。 | |||
T10652 |
Vimseltinib
DCC-3014 |
c-Fms; CSF-1R; c-Kit | Tyrosine Kinase/Adaptors |
Vimseltinib (DCC-3014) 是 c-FMS(CSF-IR) 和 c-Kit 抑制剂,IC50值分别为 <0.01 μM 和 0.1-1 μM。 | |||
T13178 |
Toceranib
托西尼布,PHA 291639E,SU11654 |
VEGFR; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Toceranib (PHA 291639E) 是口服具有活力的受体酪氨酸激酶 (RTK) 抑制剂,能有效抑制PDGFR,VEGFR,Kit,抑制 PDGFRβ 和 Flk-1/KDR 的Ki 分别为 5 nM 和 6 nM。它具有抗肿瘤和抗血管生成作用,用于研究犬肥大细胞肿瘤。 | |||
T1836 |
AZD2932
|
VEGFR; FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
AZD2932是一种多靶点激酶抑制剂,细胞试验中能够抑制 VEGFR2 (IC50:8 nM),PDGFβ (IC50:4 nM),PDGFβ (IC50:7 nM) 和 PDGFβ (IC50:9 nM)。 | |||
TQ0235 |
AC710
|
FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
AC710是一种 PDGFR 抑制剂,能够作用于 FLT3 (Kd:0.6),CSF1R (Kd:1.57),KIT (Kd:1),PDGFRα (Kd:1.3) 和 PDGFRβ (Kd:1.0)。 | |||
T2115 |
Pexidartinib
PLX-3397 |
Apoptosis; c-Fms; FLT; CSF-1R; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Pexidartinib (PLX-3397) 是具有口服活性的选择性ATP-竞争性的集落刺激因子 1 和c-Kit 抑制剂,IC50值分别为 20 和 10 nM。它可诱导细胞凋亡,具有抗肿瘤活性。 | |||
T22349 |
JNJ-38158471
CS-2660 |
VEGFR; c-RET; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
JNJ-38158471 (CS-2660) 是一种耐受性好的,有口服活性的、高效的、选择性的 VEGFR-2抑制剂 (IC50:40 nM),还能抑制 Ret (IC50:180 nM) 和 Kit (IC50:500 nM)。 | |||
T4191 |
Multi-kinase inhibitor 1
Multi-kinase inhibitor I |
Others; Bcr-Abl; PDGFR; c-Kit | Angiogenesis; Cytoskeletal Signaling; Others; Tyrosine Kinase/Adaptors |
Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) 是多激酶抑制剂。它有用于导致与酪氨酸激酶活性异常或失控有关的疾病或失调的潜力,特别是与c-Kit,PDGF-R,Bcr-abl 活性相关的疾病。 | |||
T0097L |
Pazopanib
帕唑帕尼,GW786034 |
VEGFR; FGFR; PDGFR; c-Kit; Autophagy | Angiogenesis; Autophagy; Tyrosine Kinase/Adaptors |
Pazopanib (GW786034) 是一种小分子抑制剂,可抑制多种具有潜在抗肿瘤活性的蛋白酪氨酸激酶。它抑制VEGFR1、VEGFR2、VEGFR3、PDGFRβ、c-Kit、FGFR1和c-Fms 的IC50分别为10、30、47、84、74、140和146 nM。 | |||
T2288L |
Motesanib Diphosphate
Motesanib,AMG 706,二磷酸莫替沙尼 |
VEGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Motesanib Diphosphate (AMG 706) 是一种有效的VEGFR1/2/3的 ATP 竞争性抑制剂,IC50值为 2 nM/3 nM/6 nM,与对 Kit 的选择性相似,是 PDGFR 和 Ret 的 10 倍多。 | |||
T0520 |
Lenvatinib
仑伐替尼,E7080 |
VEGFR; FGFR; c-RET; PDGFR; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Lenvatinib (E7080) 是一种多靶点受体酪氨酸激酶抑制剂,抑制 VEGFR1-3、FGFR1-4、KIT、PDGFR 和 RET 等,具有口服活性。Lenvatinib 对 VEGFR2 和 VEGFR3 的抑制活性最强 (IC50=4/5.2 nM)。Lenvatinib 具有强效抗肿瘤活性。 | |||
T2624 |
OSI-930
OSI 930,噻尔非尼 |
Apoptosis; c-Fms; Raf; VEGFR; FLT; CSF-1R; Src; c-Kit | Angiogenesis; Apoptosis; MAPK; Tyrosine Kinase/Adaptors |
OSI-930 是 Kit,KDR 和 CSF-1R (c-Fms)的口服选择性抑制剂,IC50分别为 80 nM,9 nM 和 15 nM。它具有抗肿瘤活性,靶向肿瘤中的癌细胞增殖和血管生成。它还适度抑制 Flt-1,c-Raf 和 Lck,并且对 PDGFRα/β,Flt-3和 Abl 具有较弱的抑制活性。 | |||
T2609 |
Masitinib
AB1010,马赛替尼 |
Apoptosis; FAK; c-Fms; FGFR; Bcr-Abl; PDGFR; Src; c-Kit; Hck | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Masitinib (AB1010) 是生物口服可利用的选择性 c-Kit 抑制剂 (对于人重组c-Kit,IC50=200 nM),它还抑制PDGFRα/β(IC50s=540/800 nM),Lyn(对 LynB 的IC50=510 nM),Lck,较小程度上抑制FGFR3和FAK。它有抗增殖,促凋亡活性,且毒性低。 | |||
T8482 |
Ripretinib
DCC-2618,瑞普替尼 |
Apoptosis; VEGFR; FLT; PDGFR; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Ripretinib (DCC-2618) 是一种口服生物利用的,选择性 KIT 和 PDGFRA 开关控制抑制剂,具有抗肿瘤作用并诱导细胞凋亡。它专门针对 KIT 和 PDGFRA 的野生型和突变型并与之结合在其开关口袋结合位点,从而防止这些激酶从无活性构象转变为有活性构象,并使它们的野生型和突变体形式失活。 | |||
T41003 |
KG5
|
Raf; FLT; PDGFR; c-Kit | Angiogenesis; MAPK; Tyrosine Kinase/Adaptors |
KG5 是 PDGFRβ 和 B-Raf 的双重变构抑制剂,对 PDGFRβ 和 PDGFRα 的 Kd 分别为 520 nM 和 300 nM。 KG5 抑制 FLT3、KIT 和 c-Raf,具有抗癌和抗血管生成活性。 | |||
T2516 |
Amuvatinib
MP470,HPK 56 |
Apoptosis; FLT; c-Met/HGFR; c-RET; DNA/RNA Synthesis; PDGFR; c-Kit | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Tyrosine Kinase/Adaptors |
Amuvatinib (MP470) 是一种多靶点酪氨酸激酶抑制剂,对突变 c-Kit,PDGFRα,Flt3,c-Met 和 c-Ret 具有活性。它还是一种 DNA 修复抑制剂,靶向蛋白 DNA 修复 RAD51,从而破坏 DNA 损伤修复,具有抗肿瘤活性。 | |||
T2051 |
SKLB4771
FLT3-IN-1,FLT3-IN-1 |
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
SKLB4771 (FLT3-IN-1) 是一种新型的、高效的 Flt3 抑制剂 (IC50:10nM)。 | |||
T6230 |
Imatinib
伊马替尼,STI571,CGP057148B,ST-1571 |
SARS-CoV; Bcr-Abl; PDGFR; c-Kit; Autophagy | Angiogenesis; Autophagy; Cytoskeletal Signaling; Microbiology/Virology; Tyrosine Kinase/Adaptors |
Imatinib (STI571) 是一种多靶点受体酪氨酸激酶抑制剂,可选择性抑制 BCR/ABL、v-Abl、PDGFR、c-kit 等激酶活性,具有口服活性。Imatinib 具有抗肿瘤活性,可用于治疗慢性粒细胞白血病。 | |||
T4053 |
AST 487
NVP-AST 487 |
VEGFR; FLT; c-RET; Bcr-Abl; c-Kit | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
AST 487 (NVP-AST 487) 是 RET 激酶抑制剂 (IC50:880 nM),能够抑制 RET 自磷酸化,及下游效应器激活,也抑制 Flt-3 (IC50:520 nM)。 | |||
T8541 |
Lenvatinib mesylate
仑伐替尼甲酸盐,E7080 (mesylate),乐伐替尼 |
VEGFR; FGFR; c-RET; PDGFR; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Lenvatinib mesylate (E7080 (mesylate)) 是一种口服具有活力的,多靶点酪氨酸激酶抑制剂,能够抑制血管内皮生长因子受体(VEGFR1-3),成纤维细胞生长因子受体(FGFR1-4),干细胞因子受体(KIT),血小板衍生生长因子受体(PDGFR),转染期间重排(RET),具有效抗癌作用。 | |||
T7861 |
Flumatinib mesylate
甲磺酸氟马替尼/氟马替尼,HHGV678 mesylate,甲磺酸氟马替尼 |
Bcr-Abl; PDGFR; c-Kit | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Flumatinib mesylate (HHGV678 mesylate) 是一种具有口服活性的选择性Bcr-Abl 抑制剂,能够作用于 c-Abl (IC50:1.2 nM),PDGFRβ (IC50:307.6 nM) 和 c-Kit (IC50:665.5 nM)。 | |||
T35570 |
Chiauranib
CS2164,西奥罗尼 |
c-Fms; VEGFR; FLT; PDGFR; c-Kit; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
Chiauranib 是一种针对肿瘤血管生成的多靶点抑制剂,具有强大的抗癌作用。 Chiauranib 有效抑制血管生成相关激酶(VEGFR1、VEGFR2、VEGFR3、PDGFRα 和 c-Kit)、有丝分裂相关激酶 Aurora B 和慢性炎症相关激酶 CSF1R,IC50 值范围为 1-9 nM。 | |||
T8544 |
Masitinib mesylate
甲磺酸马赛替尼,AB-1010 mesylate,马赛替尼 |
Apoptosis; FAK; FGFR; PDGFR; Src; c-Kit | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Masitinib mesylate (AB-1010 mesylate) 是一种生物口服可利用的选择性 c-Kit 抑制剂,IC50 为 200 nM。它还抑制 PDGFRα/β,IC50值为540/800 nM,对 LynB 的 IC50为510 nM。它的毒性低,有抗增殖和促凋亡活性。 | |||
T1621 |
Imatinib Mesylate
甲磺酸伊马替尼,ST-1571 Mesylate,STI-571,CGP-57148B |
Bcr-Abl; PDGFR; c-Kit; Autophagy | Angiogenesis; Autophagy; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Imatinib Mesylate (STI-571) 是一种酪氨酸激酶受体抑制剂,具有抗肿瘤活性,对 v-Abl、c-Kit 和 PDGFR 的 IC50 分别为 0.6 μM、0.1 μM 和 0.1 μM。 | |||
T6711 |
Tyrphostin AG1296
Tyrphostin AG 1296,AG 1296 |
Apoptosis; FGFR; FLT; PDGFR; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Tyrphostin AG1296 (Tyrphostin AG 1296) 抑制人PDGF α和β受体以及相关干细胞因子受体的信号传导,是一种选择性血小板衍生生长因子受体抑制剂,IC50值为 0.8 μM。 | |||
T7394 |
Toceranib Phosphate
SU11654 phosphate,PHA 291639 phosphate,托西尼布磷酸盐 |
VEGFR; Tyrosinase; PDGFR; c-Kit | Angiogenesis; Proteases/Proteasome; Tyrosine Kinase/Adaptors |
Toceranib Phosphate (SU11654 phosphate) 是有效的、具有口服活性的酪氨酸激酶 (RTK) 受体抑制剂,能抑制PDGFR,VEGFR,Kit,抑制 PDGFRβ 和 Flk-1/KDR 的Ki 分别为 5 nM 和 6 nM。它具有抗肿瘤和抗血管生成作用,可用于研究犬肥大细胞肿瘤。 | |||
T4315 |
Ki20227
N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲 |
c-Fms; VEGFR; CSF-1R; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Ki20227 是一种高效的、口服具有活性的、选择性的CSF1R(c-Fms 酪氨酸激酶)抑制剂,对 CSF1R,VEGFR2,c-Kit 和PDGFRβ的IC50分别为 2 nM,12 nM,451 nM 和 217 nM。它可以阻止破骨细胞分化和溶骨性破坏。 | |||
T1792 |
Regorafenib
BAY 73-4506,瑞戈非尼,Fluoro-Sorafenib,瑞格非尼 |
Raf; VEGFR; c-RET; PDGFR; c-Kit; Autophagy | Angiogenesis; Apoptosis; Autophagy; MAPK; Tyrosine Kinase/Adaptors |
Regorafenib (BAY 73-4506) 是一种多靶点受体酪氨酸激酶抑制剂,抑制 RET、C-RAF、VEGFR2、c-Kit、VEGFR1 和 PDGFRβ (IC50=1.5/2.5/4.2/7/13/22 nM),具有口服活性。Regorafenib 具有抗肿瘤和抗血管生成活性。 | |||
T1667 |
Tandutinib
MLN518,CT53518,NSC726292,坦度替尼 |
Apoptosis; FLT; CSF-1R; PDGFR; Src; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Tandutinib (CT53518) 是一种选择性 FLT3抑制剂,其 IC50为 0.22 μM。它还抑制c-Kit 和PDGFR,其IC50分别为 0.17 μM 和 0.20 μM。它可穿透血脑屏障,用于急性骨髓性白血病。 | |||
T2586 |
Cabozantinib
卡博替尼,XL184,BMS-907351 |
Apoptosis; VEGFR; FLT; c-Met/HGFR; c-RET; TAM Receptor; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Cabozantinib (XL184) 是一种多靶点酪氨酸激酶受体抑制剂,可以抑制 VEGFR2、c-Met、Kit、Axl 和 Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM)。Cabozantinib 具有抗肿瘤和抗血管生成活性。 | |||
T4349 |
Sitravatinib
MG516,MGCD516 |
Discoidin Domain Receptor (DDR); VEGFR; FLT; Trk receptor; TAM Receptor; c-Kit; Ephrin Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
Sitravatinib (MGCD516) 是一种有口服活性的受体酪氨酸激酶抑制剂。它单独使用即具有有效的抗肿瘤功效,且通过促进抗肿瘤免疫微环境增强了 PD-1 阻断的活性。 | |||
T3211 |
Midostaurin
米哚妥林,N-Benzoylstaurosporine,PKC412,CGP41231,CGP 41251,苯甲酰基十字孢碱 |
Others; PKC | Chromatin/Epigenetic; Cytoskeletal Signaling; Others |
Midostaurin (PKC412) 是一种多靶点蛋白激酶抑制剂,有抗肿瘤活性,对 PKCα/β/γ、Syk、Flk-1、Akt、PKA、c-Kit、c-Fgr、c-Src、FLT3、PDFRβ和VEGFR1/2的IC50值范围为 22 到500 nM 之间。 | |||
T6479 |
Dovitinib lactate hydrate
Dovitinib (TKI258) Lactate,多韦替尼,Dovitinib Lactate,TKI258 |
VEGFR; FGFR; FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Dovitinib lactate hydrate (TKI258) 是一种多靶点的酪氨酸激酶抑制剂,抑制 FLT3,c-Kit,FGFR1/3,VEGFR1/2/3和 PDGFRα/β的 IC50值分别为 1,2,8/9,10/13/8,27/210 nM。 | |||
T6930 |
Pazopanib Hydrochloride
GW786034,Pazopanib HCl,GW786034 HCl,盐酸帕唑帕尼,Votrient HCl,Armala |
c-Fms; VEGFR; FGFR; PDGFR; c-Kit; Autophagy | Angiogenesis; Autophagy; Tyrosine Kinase/Adaptors |
Pazopanib Hydrochloride (Votrient HCl) 是一种多靶点抑制剂,抑制 VEGFR1、VEGFR2、VEGFR3、PDGFRβ、c-Kit、FGFR1和c-Fms 的IC50分别为10、30、47、84、74、140和146 nM。 | |||
T7104 |
Dovitinib lactate
CHIR-258 lactate,多韦替尼乳酸盐,TKI-258 lactate |
VEGFR; FGFR; FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Dovitinib lactate (TKI-258 lactate) 是一种多靶点的酪氨酸激酶抑制剂,抑制FLT3,c-Kit,FGFR1/3,VEGFR1/2/3和PDGFRα/β的IC50值分别为 1,2,8/9,10/13/8,27/210 nM。 | |||
T6289 |
Dovitinib
TKI258,多韦替尼,CHIR-258,度维替尼 |
VEGFR; FGFR; FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Dovitinib (CHIR-258) 是一种口服有效的、多靶点的酪氨酸激酶 (RTK) 抑制剂,具有抗肿瘤作用。 | |||
T5164 |
Cabozantinib hydrochloride
XL184,Cabozantinib hydrochloride (849217-68-1(free base)),BMS-907351,盐酸卡博替尼 |
VEGFR; FLT; c-Met/HGFR; TAM Receptor; c-Kit; ROR | Angiogenesis; Metabolism; Tyrosine Kinase/Adaptors |
Cabozantinib hydrochloride (XL184) 是一种有效的泛酪氨酸激酶抑制剂,可抑制 VEGFR2、c-Met、Kit、Axl 和 Flt4(IC50:0.035、1.3、4.6、7 和 6 nM)。 | |||
T2514 |
Linifanib
利尼伐尼,ABT-869,RG3635,AL-39324 |
Apoptosis; c-Fms; VEGFR; FLT; CSF-1R; PDGFR; c-Kit; Autophagy | Angiogenesis; Apoptosis; Autophagy; Tyrosine Kinase/Adaptors |
Linifanib (AL-39324) 是一种高效口服的VEGFR 和PDGFR 家族多靶点抑制剂,具有显著的抗肿瘤活性。它对无关 RTKs、可溶性酪氨酸激酶或丝氨酸/苏氨酸激酶的活性要低得多。它是特异性 miR-10b 抑制剂,阻断miR-10b 的生物合成。 | |||
T1925 |
PLX647
|
c-Fms; c-Kit | Tyrosine Kinase/Adaptors |
PLX647 是具有口服活性的、高效的、特异性的FMS 和KIT 双激酶抑制剂,IC50分别为 28 和 16 nM。它 (1 μM) 在 400 个激酶组中显示出对 FMS 和 KIT 有选择性,但 FLT3 和 KDR 除外 (IC50=91 和 130 nM)。 | |||
T22256 |
c-Kit-IN-5-1
3-(2-Aminoquinazolin-6-yl)-4-methyl-1-(4-(oxazol-2-yl)phenyl)pyridin-2(1H)-one,AMG-25,3-(2-aminoquinazolin-6-yl)-4-methyl-1-[4-(1,3-oxazol-2-yl)phenyl]pyridin-2-one |
c-Kit | Tyrosine Kinase/Adaptors |
c-Kit-IN-5-1 (AMG-25) 是一种新型的、高效的、选择性的 c-Kit 抑制剂。 | |||
T78305 |
Briquilimab
JSP-191 |
||
Briquilimab (JSP-191) 是针对 CD117 (c-Kit) 的无毒人源化单克隆抗体,用于消耗造血干细胞 (HSC)。它被应用于重度联合免疫缺陷 (SCID) 治疗中,以清空宿主骨髓生态位,为供体造血干细胞移植及免疫重建创造条件。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-00777 |
CD117 Protein, Mouse, Recombinant (His)
ckit,PBT,SCFR,KIT,CD117,c-kit |
Mouse | HEK293 Cells |
The c-kit proto-oncogen (CD 117) has been shown to be present in several cell types including normal and neoplastic hemopoietic cells. Among normal BM cells, CD117 expression has been found in about half of the CD34 precursors including progenitors committed to the erythroid, granulo-monocytic, and megakaryocytic cell lineages. CD117 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 56.63 kDa and the accession number is P05... | |||
TMPK-01270 |
CD117 Protein, Cynomolgus/Rhesus macaque, Recombinant (His)
KIT,PBT,c-kit,CD117,SCFR,ckit |
Cynomolgus,Rhesus | HEK293 Cells |
The c-kit proto-oncogen (CD117) has been shown to be present in several cell types including normal and neoplastic hemopoietic cells. Among normal BM cells, CD117 expression has been found in about half of the CD34 precursors including progenitors committed to the erythroid, granulo-monocytic, and megakaryocytic cell lineages. | |||
TMPK-00805 |
CD117 Protein, Human, Recombinant (His & Avi), Biotinylated
CD117,EC 2.7.10,EC 2.7.10.1,c-kit,KIT,SCFR... |
Human | HEK293 Cells |
The c-kit proto-oncogen (CD 117) has been shown to be present in several cell types including normal and neoplastic hemopoietic cells. Among normal BM cells, CD117 expression has been found in about half of the CD34 precursors including progenitors committed to the erythroid, granulo-monocytic, and megakaryocytic cell lineages. CD117 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 58.60 kDa and the... | |||
TMPY-01935 |
c-Kit Protein, Human, Recombinant (His)
PBT,CD117,v-kit Hardy-Zuckerman 4 feline s... |
Human | HEK293 Cells |
c-Kit Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 56.7 kDa and the accession number is P10721-2. | |||
TMPY-04051 |
c-Kit Protein, Human, Recombinant (hFc)
SCFR,v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene h... |
Human | HEK293 Cells |
c-Kit Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 82 kDa and the accession number is P10721-2. | |||
TMPJ-00402 |
CD117 Protein, Human, Recombinant (hFc)
KIT,CD117,v-kit Hardy-Zuckerman 4 feline s... |
Human | HEK293 Cells |
C-Kit/SCF R is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). c-Kit contains 5 Ig-like C2-type (immunoglobulin-like) domains and 1 protein kinase domain. It belongs to the protein kinase superfamily and CSF-1/PDGF receptor subfamily. SCF R expression on mast cells enables them to infiltrate SCF-secreting tumors where they promote tumor growth and induce local immune suppression. SCF R is up-regulated on dendritic cells by Th2-orTh17-biasing sti... | |||
TMPY-01802 |
c-Kit Protein, Mouse, Recombinant (His)
SCO5,SCO1,Bs,Gsfsco1,v-kit Hardy-Zuckerman 4 feline sarcoma ... |
Mouse | HEK293 Cells |
c-Kit Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 57 kDa and the accession number is P05532-1. | |||
TMPY-06656 |
c-Kit Protein, Human, Recombinant (His & Avi), Biotinylated
CD117,SCFR,C-Kit,v-kit Hardy-Zuckerman 4 f... |
Human | HEK293 Cells |
c-Kit Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag. The predicted molecular weight is 58.50 kDa and the accession number is P10721-2. | |||
TMPY-03567 |
c-Kit Protein, Human, Recombinant (aa 50-190, His)
SCFR,PBT,C-Kit,CD117,v-kit Hardy-Zuckerman... |
Human | E. coli |
c-Kit Protein, Human, Recombinant (aa 50-190, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 17.9 kDa and the accession number is P10721-1. | |||
TMPY-04564 |
c-Kit Protein, Human, Recombinant (aa 540-972, His & GST)
C-Kit,PBT,SCFR,CD117,v-kit Hardy-Zuckerman... |
Human | Baculovirus Insect Cells |
c-Kit Protein, Human, Recombinant (aa 540-972, His & GST) is expressed in Baculovirus insect cells with His and GST tag. The predicted molecular weight is 76.8 kDa and the accession number is P10721-2. | |||
TMPY-01801 |
c-Kit Protein, Mouse, Recombinant (hFc)
SCO1,Gsfsco1,W,v-kit Hardy-Zuckerman 4 feline sarcoma viral ... |
Mouse | HEK293 Cells |
c-Kit Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 82.5 kDa and the accession number is P05532-1. | |||
TMPK-00184 |
CD20 Protein, Human, Recombinant (His & Avi), Biotinylated
MS4A-1,CD20,B-lymphocyte surface antigen B1,Membran... |
Human | E. coli |
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20... | |||
TMPK-00183 |
CD20 Protein, Human, Recombinant (His & Avi)
MS4A2,Ly-44,LEU-16,MS4A1,Bp35,CD20 receptor,CVID5,M... |
Human | E. coli |
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20... |